source
- Pfizer strikes over $500M partnership with Enodia to develop Sec61-targeting small-molecule drugsPfizer's venture arm helped fund Enodia Therapeutics with a $25 million seed round earlier this year. The two companies have now announced a collaboration that could be worth more than $500 millio…
- Analysts focus on RevMed pancreatic cancer launch and Merck data push ahead of Q3 earningsJohnson & Johnson is set to open the third quarter earnings reporting period, with analysts keen to hear about any business development news and launch execution updates. RevMed’s upcoming launch…